AZ and Ionis' heart-disease drug flops in pivotal ATTR-CM trial
TL;DR Summary
AstraZeneca and Ionis reported that their heart-disease drug Wainua failed to outperform placebo in a pivotal trial for ATTR-CM (transthyretin-mediated amyloid cardiomyopathy), not reducing cardiovascular death or clinical events, and the news pushed both companies' shares down in premarket trading.
Topics:business#astrazeneca#attr-cm#biotech#clinical-trial-failure#ionis-pharmaceuticals#transthyretin-mediated-amyloid-cardiomyopathy
- AstraZeneca, Ionis report major trial failure with heart disease drug STAT
- AstraZeneca stock drops 9% after heart drug trial miss deals rare blow to pharma powerhouse CNBC
- AstraZeneca, Ionis Stocks Stumble After Heart Drug Fails Key Trial WSJ
- AstraZeneca's Wainua fails key heart disease trial, shares tumble Reuters
- IONS Stock Heads Toward Biggest Single-Day Slump In Over 5 Years – Retail Calls It ‘Opportunity Of A Lifetime’ Yahoo Finance
Reading Insights
Total Reads
1
Unique Readers
1
Time Saved
2 min
vs 2 min read
Condensed
89%
375 → 40 words
Want the full story? Read the original article
Read on STAT